The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
We have worked hard over the past few months to ensure our communications are accurate transparent
and timely. The RNS we released yesterday about our headline results was a major milestone for ValiRx and
my intent was to ensure that all shareholders received a clear, fact-based up-date on the phase I/II clinical
trial of VAL201, within the promised timeframe. To repeat the essence of my comments in the RNS, the results are exciting and the culmination of a lot of
hard work by everyone involved in the trial. The data for this first clinical trial of VAL201 has been generated
using the utmost caution in sequentially dosing patients and has taken some considerable time. The
headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug with
a favourable side effect profile. In light of this and the positive response rate we intend to share these
results with potential industry partners to evaluate options for further clinical development of VAL201. Our ultimate goal is captured well in the words of our Medical Monitor, Professor Alan Boyd: “Development
of effective treatments with low-side effects for patients with prostate cancer who have relapsed after
radiotherapy is essential and will improve the lives of patients during treatment.” Best wishes,
Suzy
Dr Suzanne Dilly
Dr Suzy Dilly, Chief Executive Officer commented: "I am delighted to be able to share these exciting results today, which are an accumulation of a lot of work by the wider team, both within and external to ValiRx. While considering these results it is important to remember that this is only the first clinical trial using VAL201, so this data has been generated using the utmost caution in sequentially dosing patients. Nevertheless, the headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug. With this data in hand, future studies will investigate optimal dosing strategies for VAL201 and help confirm these early indications of a positive response rate."
Professor Alan Boyd, Consultant Pharmaceutical Physician and Medical Monitor for the study commented: "Development of effective treatments with low-side effects for patients with prostate cancer who have relapsed after radiotherapy is essential and will improve the lives of patients during treatment. I am pleased to have contributed to a project that has demonstrated such a good safety and tolerability profile while giving the first indications of a favourable effect on the patient's disease."
Hi guys, just a quick question. Would any of you consider moving your pension to a SIPP? With the market below very low, would now be a good time to transfer out my BT pension, and invest it on some super low bank stock for example?
I want to get a feel of what people think of the idea.
Obviously I'll seek proper financial advice. Many thanks